HighTower Advisors’s Takeda Pharmaceutical TAK Stock Holding History

HighTower Advisors’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.53M	Sell	95,466 -7,616	-7%	-$126K	﹤0.01%	1955
2026 Q1	$1.91M	Buy	103,082 +8,254	+9%	+$145K	﹤0.01%	1740
2025 Q4	$1.48M	Sell	94,828 -4,014	-4%	-$57.4K	﹤0.01%	1856
2025 Q3	$1.45M	Buy	98,842 +2,517	+3%	+$37.4K	﹤0.01%	1842
2025 Q2	$1.49M	Buy	96,325 +8,580	+10%	+$127K	﹤0.01%	1748
2025 Q1	$1.3M	Sell	87,745 -36,694	-29%	-$514K	﹤0.01%	1790
2024 Q4	$1.65M	Buy	124,439 +1,852	+2%	+$25.4K	﹤0.01%	1634
2024 Q3	$1.74M	Buy	122,587 +81,653	+199%	+$1.16M	﹤0.01%	1604
2024 Q2	$532K	Sell	40,934 -52,123	-56%	-$690K	﹤0.01%	2280
2024 Q1	$1.3M	Buy	93,057 +8,787	+10%	+$128K	﹤0.01%	1653
2023 Q4	$1.21M	Buy	84,270 +550	+0.7%	+$7.8K	﹤0.01%	1743
2023 Q3	$1.3M	Buy	83,720 +12,423	+17%	+$192K	﹤0.01%	1616
2023 Q2	$1.12M	Buy	71,297 +38,651	+118%	+$633K	﹤0.01%	1696
2023 Q1	$523K	Buy	32,646 +6,204	+23%	+$98.8K	﹤0.01%	2076
2022 Q4	$414K	Buy	26,442 +3,015	+13%	+$42.1K	﹤0.01%	2260
2022 Q3	$304K	Sell	23,427 -719	-3%	-$10K	﹤0.01%	2330
2022 Q2	$340K	Sell	24,146 -4,180	-15%	-$59.7K	﹤0.01%	2276
2022 Q1	$404K	Buy	28,326 +1,973	+7%	+$29K	﹤0.01%	2325
2021 Q4	$360K	Sell	26,353 -5,260	-17%	-$73.8K	﹤0.01%	2366
2021 Q3	$512K	Sell	31,613 -611	-2%	-$10.3K	﹤0.01%	2041
2021 Q2	$544K	Buy	32,224 +5,666	+21%	+$96.5K	﹤0.01%	2004
2021 Q1	$485K	Buy	26,558 +3,694	+16%	+$66.5K	﹤0.01%	1992
2020 Q4	$416K	Sell	22,864 -1,734	-7%	-$30.4K	﹤0.01%	1723
2020 Q3	$440K	Buy	24,598 +889	+4%	+$16.2K	﹤0.01%	1636
2020 Q2	$425K	Buy	23,709 +4,694	+25%	+$84.3K	﹤0.01%	1546
2020 Q1	$293K	Buy	19,015 +3,395	+22%	+$61.5K	﹤0.01%	1586
2019 Q4	$309K	Sell	15,620 -454	-3%	-$8.69K	﹤0.01%	1705
2019 Q3	$275K	Sell	16,074 -13,865	-46%	-$240K	﹤0.01%	1851
2019 Q2	$534K	Buy	29,939 +919	+3%	+$16.7K	﹤0.01%	1485
2019 Q1	$591K	Buy	+29,020	New	+$584K	﹤0.01%	1374

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

HighTower Advisors's TAK Position: Q2 2026 in Review

HighTower Advisors reduced its Takeda Pharmaceutical (TAK) stake by 7.4% in Q2 2026, selling an estimated $126K and leaving 95,466 shares worth $1.53M. The position accounts for ﹤0.01% of the portfolio, ranked #1955.

HighTower Advisors first reported a position in TAK in Q1 2019 and has held it in 30 quarters since. The position peaked at $1.91M in Q1 2026. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

HighTower Advisors held 95,466 shares of Takeda Pharmaceutical worth $1.53M as of Q2 2026.
HighTower Advisors sold 7,616 Takeda Pharmaceutical shares in Q2 2026, an estimated $126K.
Takeda Pharmaceutical made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #1955 holding.
HighTower Advisors first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 30 quarters since.
HighTower Advisors's Takeda Pharmaceutical position peaked at $1.91M in Q1 2026.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.